Clinical trials: Diabetic Nephropathy
Nephropathy, Hypoxia
Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes.
- Conditions
- Nephropathy, Hypoxia, Mitochondrial Alteration, Type 1 Diabetes
- Trial name
- Astronaut (NCT04193566)
- Testing
- Forxiga
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Proteinuria
Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan
Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage.
- Trial name
- NCT06491940
- Testing
- Losartan, Losartan + Hydrochlorothiazide
- Where
- Pakistan
- Volunteers
- 234 people
- Sponsor
- RESnTEC, Institute of Research
Type 2 Diabetes Mellitus
Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
Recent studies in rodents show that glucagon-like peptide-1 (GLP-1) analogues protect against diabetic nephropathy. We hypothesise that this is also the case in humans.
- Trial name
- NCT01664676
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- University of Aarhus
Type 2 Diabetes, Microvascular Function
The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes
Patients with type 2 diabetes have an increased risk of developing vascular complications. Microvascular dysfunction might be caused by the increased production of methylglyoxal under hyperglycaemic conditions.
- Conditions
- Type 2 Diabetes, Microvascular Function, Retinopathy, Diabetic, Nephropathy, Diabetic
- Trial name
- PYRAMID (NCT06376240)
- Testing
- Pyridoxamine 300mg per day
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Maastricht University Medical Center
Diabetic Nephropathy
Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy
The investigators designed a randomized parallel controlled clinical study, selected 98 cases of diabetic nephropathy patients with urinary protein > 1g, randomly assigned into the Kunxian capsule + irbesartan group or irbesartan…
- Trial name
- NCT04981613
- Testing
- Kunxian capsule
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Epilepsy, Diabetic Nephropathy
Study on the Population Pharmacokinetics of Levetiracetam in Epileptic Patients With Diabetic Kidney Disease
The individualized drug delivery system of levetiracetam based on population pharmacokinetics and quantitative pharmacology model in patients with epilepsy complicated by diabetic kidney disease was established.
- Trial name
- NCT05330390
- Testing
- Levetiracetam
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Second Hospital of Shandong University
SLE, Lupus Nephritis
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
This study aims to assess sodium glucose linked transoprter inhibitors(SGT2i) role in regression of ongoing kidney and cardiac diseases among lupus nephritis patient either diabetic or non-diabetic under different…
- Conditions
- SLE, Lupus Nephritis, SGLT2 Inhibitors
- Trial name
- NCT05748925
- Testing
- dapagliflozin
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Mansoura University
Diabetic Kidney Disease, Type 1 Diabetes
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes.
- Trial name
- RT1D (NCT05822609)
- Testing
- Semaglutide
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Washington
Diabetic Nephropathies, Diabetes Mellitus, Type II
Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy
Background The relationship between long-term heavy lead exposure and chronic interstitial nephropathy is well recognized in the previous literatures.
- Trial name
- NCT00237952
- Testing
- EDTA chelating agents
- Where
- 2 sites in China
- Sponsor
- Chang Gung Memorial Hospital
Diabetic Nephropathies
Nitric Oxide (NO) Activity and Diabetic Nephropathy
Experimental data suggest that oxidative stress and endothelial dysfunction are key players in the pathogenesis of diabetic nephropathy.
- Trial name
- NCT00136188
- Testing
- Folic Acid
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446459
- Testing
- mycophenolate mofetil (CellCept)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
Diabetic Nephropathies
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
Diabetic kidney disease remains the leading cause of end-stage kidney disease (ESKD), rising in frequency in parallel with the epidemic of diabetes worldwide.
- Trial name
- PERL-FENO (NCT04929379)
- Testing
- Fenofibrate
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Alessandro Doria
Diabetic Nephropathies
The Effects of TMZ on Diabetic Nephropathy
With the improvement of people's living standard, the prevalence of Diabetes is increasing year by year. In present, 350 million people worldwide are suffering from diabetes, and by 2035, there will be as high as 600 million.
- Trial name
- NCT05147194
- Testing
- Trimetazidine
- Volunteers
- 150 people
- Sponsor
- Tongji Hospital
Diabetic Nephropathies
Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
This study is a single center open-label randomized controlled trial designed to evaluate the efficacy of calcitriol plus losartan therapy in subjects with type II diabetes and macroalbuminuria.
- Trial name
- IDEAL (NCT02410005)
- Testing
- Calcitriol, Losartan
- Where
- 3 sites in United States, Qatar
- Volunteers
- 56 people
- Sponsor
- Weill Cornell Medical College in Qatar
Diabetes Mellitus, Diabetic Kidney Disease
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
SGLT2 inhibitors such as ertugliflozin improve blood pressure and kidney outcomes in people living with diabetes through incompletely understood mechanisms, however, not all patients treated with SGLT2 inhibition have improved…
- Conditions
- Diabetes Mellitus, Diabetic Kidney Disease, Hypertension
- Trial name
- DESIGN (NCT05727579)
- Testing
- Salt-Diet and/or Ertugliflozin, Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetic Nephropathy
Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy
The investigators hypothesize that, LPD supplemented with ketoanalogs will reduce urine podocyte loss and lower the angiotensinogen level in the urine.
- Trial name
- NCT01300273
- Testing
- Compound α-Ketoacid Tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diabetic Kidney Disease
Non Diabetic Causes of Chronic Kidney Disease in Type 2 Diabetic Patients
Determination of the possible causes of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus with an atypical presentations of renal disease for proper management and thus improving renal outcome.
- Trial name
- NCT05021705
- Volunteers
- 60 people
- Sponsor
- Assiut University
Diabetes Mellitus, Diabetic Nephropathies
Effects of Fenofibrate Therapy in Diabetic Nephropathy
Diabetic nephropathy (DN) is a common cause of end-stage renal disease (ESRD) and accounts for nearly half of all new patients starting dialysis in Singapore, the country with the highest rates of DN in the Asia-Pacific region.
- Trial name
- NCT03869931
- Testing
- Fenofibrate
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Singapore General Hospital
Glomerulonephritis
Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis
This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.
- Trial name
- NCT06835322
- Testing
- Finerenone
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Chronic Kidney Diseases, Diabetes Mellitus
Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease
The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, markers of inflammation, and physical function in individuals with advanced chronic kidney…
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Diabetic Nephropathies
- Trial name
- NCT03325322
- Testing
- Fisetin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic